

References

1. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. *European Journal of Cancer*. 2018;103:356-387. doi:10.1016/j.ejca.2018.07.005
2. Hofmarcher T, Brådvik G, Svedman C, Lindgren P, Jönsson B, Wilking N. Comparator Report on Cancer in Europe 2019. Published online 2019:230.
3. Angelis RD, Sant M, Coleman MP, et al. Cancer survival in Europe 1999–2007 by country and age: results of EURO CARE-5—a population-based study. *The Lancet Oncology*. 2014;15(1):23-34. doi:10.1016/S1470-2045(13)70546-1
4. OECD. *Cancer Care: Assuring Quality to Improve Survival*. OECD Health Policy Studies, OECD Publishing; 2013:156. doi:https://doi.org/https://doi.org/10.1787/9789264181052-en
5. World Health Organization. *Global Spending on Health: A World in Transition*. (WHO/HIS/HGF/HFWorkingPaper/19.4.); 2019. Accessed May 26, 2020. <https://apps.who.int/iris/bitstream/handle/10665/330357/WHO-HIS-HGF-HF-WorkingPaper-19.4-eng.pdf>
6. Hofmarcher T, Lindgren P, Wilking N, Jönsson B. The cost of cancer in Europe 2018. *European Journal of Cancer*. 2020;129:41-49. doi:10.1016/j.ejca.2020.01.011
7. World Health Organization. *Pricing of Cancer Medicines and Its Impacts*. World Health Organization; 2018. Accessed April 10, 2020. <https://apps.who.int/iris/bitstream/handle/10665/277190/9789241515115-eng.pdf?sequence=1&isAllowed=y>
8. Adang E, Stadhouders N, Parsons C, et al. *Verdringingseffecten binnen het Nederlandse zorgstelsel*; 2018:103. <https://www.iqhealthcare.nl/media/124601/eindrapport-verdringing-2018.pdf>
9. Nederlandse Zorgautoriteit. *Monitor geneesmiddelen in de medisch-specialistische zorg 2020*. Nederlandse Zorgautoriteit; 2020:49. http://puc.overheid.nl/doc/PUC_305909_22
10. Uyl-de Groot CA, Löwenberg B. Sustainability and affordability of cancer drugs: a novel pricing model. *Nature Reviews Clinical Oncology*. 2018;15(7):405-406. doi:10.1038/s41571-018-0027-x
11. Gurwitz JH, Pearson SD. Novel Therapies for an Aging Population: Grappling With Price, Value, and Affordability. *JAMA*. 2019;321(16):1567-1568. doi:10.1001/jama.2019.2633
12. Tarín-Arzaga L, Arredondo-Campos D, Martínez-Pacheco V, et al. Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico. *Cancer*. 2018;124(9):1946-1953. doi:10.1002/cncr.31305
13. Flume M, Bardou M, Capri S, et al. Approaches to manage 'affordability' of high budget impact medicines in key EU countries. *Journal of Market Access & Health Policy*. 2018;6(1). doi:10.1080/20016689.2018.1478539
14. World Health Organization. Health technology assessment. WHO. Accessed May 26, 2020. https://www.who.int/medical_devices/assessment/en/
15. Facey KM. Health Technology Assessment. In: Facey KM, Ploug Hansen H, Single ANV, eds. *Patient Involvement in Health Technology Assessment*. Springer; 2017:3-16. doi:10.1007/978-981-10-4068-9_1
16. Banta D, Jonsson E. History of HTA: Introduction. *International Journal of Technology Assessment in Health Care*. 2009;25(S1):1-6. doi:10.1017/S0266462309090321
17. European Network for Health Technology Assessment. EUnetHTA Joint Action 2, Work Package 8. HTA Core Model* version 3.0. Published 2016. Accessed May 27, 2020. <https://eunetha.eu/wp-content/uploads/2018/03/HTACoreModel3.0-1.pdf>
18. Jit M, Hutubessy R. Methodological challenges to economic evaluations of vaccines: is a common approach still possible? *Applied health economics and health policy*. 2016;14(3):245-252.
19. Drummond MF, Sculpher M, Claxton K, Stoddart GL, Torrance GW. *Methods for the Economic Evaluation of Health Care Programmes*. Oxford University Press; 2015. Accessed March 26, 2020. <http://jech.bmj.com/cgi/doi/10.1136/jech.41.4.355-a>

20. Polimeni JM, Vichansavakul K, Iorgulescu RI, Chandrasekara R. Why Perspective Matters In Health Outcomes Research Analyses. *International Business & Economics Research Journal (IBER)*. 2013;12(11):1503-1512. doi:10.19030/iber.v12i11.8186
21. Byford S, Raftery J. Perspectives in economic evaluation. *BMJ*. 1998;316(7143):1529-1530. doi:10.1136/bmj.316.7143.1529
22. Garrison LP, Mansley EC, Abbott TA, Bresnahan BW, Hay JW, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. *Value Health*. 2010;13(1):8-13. doi:10.1111/j.1524-4733.2009.00660.x
23. Jönsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. *Eur J Health Econ*. 2009;10(4):357-359. doi:10.1007/s10198-009-0173-2
24. Drost RMWA, Putten IM van der, Ruwaard D, Evers SMAA, Paulus ATG. Conceptualizations of the societal perspective within economic evaluations: a systematic review. *International Journal of Technology Assessment in Health Care*. 2017;33(2):251-260. doi:10.1017/S0266462317000526
25. Hoefman RJ, van Exel J, Brouwer WBF. Measuring Care-Related Quality of Life of Caregivers for Use in Economic Evaluations: CarerQol Tariffs for Australia, Germany, Sweden, UK, and US. *Pharmacoeconomics*. 2017;35(4):469-478. doi:10.1007/s40273-016-0477-x
26. de Vries LM, van Baal PHM, Brouwer WBF. Future Costs in Cost-Effectiveness Analyses: Past, Present, Future. *Pharmacoeconomics*. 2019;37(2):119-130. doi:10.1007/s40273-018-0749-8
27. Gros B, Soto Álvarez J, Ángel Casado M. Incorporation of future costs in health economic analysis publications: current situation and recommendations for the future. *Expert Rev Pharmacoecon Outcomes Res*. 2015;15(3):465-469. doi:10.1586/14737167.2015.1021689
28. Weinstein MC, Russell LB, Gold MR, Siegel JE. *Cost-Effectiveness in Health and Medicine*. Oxford university press; 1996.
29. Campbell JD, McQueen RB, Briggs A. The “e” in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. *Annals of the American Thoracic Society*. 2014;11(Supplement 2):S105-S111.
30. van Mastrigt GA, Hilgsmann M, Arts JJ, et al. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3). *Expert Review of Pharmacoeconomics & Outcomes Research*. Published online 2016:1-16.
31. Centre for Reviews Dissemination. *Systematic Reviews : CRD's Guidance for Undertaking Reviews in Health Care*. CRD, University of York; 2009.
32. Shemilt I, Aluko P, Graybill E, et al. Chapter 20: Economic evidence. In: *Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (Updated July 2019)*. ; 2019. Accessed June 29, 2020. /handbook/current/chapter-20
33. Szajewska H. Evidence-Based Medicine and Clinical Research: Both Are Needed, Neither Is Perfect. *ANM*. 2018;72(3):13-23. doi:10.1159/000487375
34. OCEBM Levels of Evidence Working Group. “The Oxford Levels of Evidence 2”. Accessed June 12, 2020. <https://www.cebm.net/index.aspx?o=5653>
35. Friedman LM, Furberg CD, DeMets DL, Reboussin DM, Granger CB. *Fundamentals of Clinical Trials*. Springer International Publishing; 2015. doi:10.1007/978-3-319-18539-2
36. Jones DS, Podolsky SH. The history and fate of the gold standard. *The Lancet*. 2015;385(9977):1502-1503. doi:10.1016/S0140-6736(15)60742-5
37. Krendyukov A. Innovative oncology products: time to revisit the strategy development? *ESMO Open*. 2019;4(5). doi:10.1136/esmoopen-2019-000571

38. Crabb N, Stevens A. *Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products*. Accessed March 24, 2020. <https://docplayer.net/18693201-Exploring-the-assessment-and-appraisal-of-regenerative-medicines-and-cell-therapy-products.html>
39. Naudet F, Sakarovich C, Janiaud P, et al. Data sharing and reanalysis of randomized controlled trials in leading biomedical journals with a full data sharing policy: survey of studies published in The BMJ and PLOS Medicine. *BMJ*. 2018;360. doi:10.1136/bmj.k400
40. Wordsworth S, Ludbrook A, Caskey F, Macleod A. Collecting unit cost data in multicentre studies. Creating comparable methods. *Eur J Health Econ*. 2005;6(1):38-44. doi:10.1007/s10198-004-0259-9
41. Clement Nee Shrive FM, Ghali WA, Donaldson C, Manns BJ. The impact of using different costing methods on the results of an economic evaluation of cardiac care: microcosting vs gross-costing approaches. *Health Econ*. 2009;18(4):377-388. doi:10.1002/hec.1363
42. Hakkaart-van Roijen L, van der Linden N, Bouwamans C, Kanter T, Swan Tan S. *Kostenhandleiding: Methodologie van Kostenonderzoek En Referentieprijzen Voor Economische Evaluaties in de Gezondheidszorg. Bijlage 1 [Costing Guideline: Methodology of Costing Studies and Reference Prices for Economic Evaluations in Health Care. Appendix 1];* 2016.
43. Bhandari A, Wagner T. Self-Reported Utilization of Health Care Services: Improving Measurement and Accuracy. *Medical Care Research and Review*. Published online August 18, 2006. doi:10.1177/1077558705285298
44. Hippisley-Cox J, Pringle M, Cater R, et al. The electronic patient record in primary care—regression or progression? A cross sectional study. *BMJ*. 2003;326(7404):1439-1443. doi:10.1136/bmj.326.7404.1439
45. Fey MF. The costs of care in haematological cancers: Health economic issues. *Hematological Oncology*. 2017;35(S1):15-19. doi:10.1002/hon.2394
46. Allen PB, Flowers CR. Balancing patient value and payer cost in hematologic malignancies: can it be done? *Expert Rev Pharmacoecon Outcomes Res*. 2018;18(2):123-126. doi:10.1080/14737167.2018.1444478
47. GCO, IARC. Globocan. Cancer today. Accessed December 3, 2019. <http://gco.iarc.fr/today/home>
48. Burns R, Leal J, Sullivan R, Luengo-Fernandez R. Economic burden of malignant blood disorders across Europe: a population-based cost analysis. *The Lancet Haematology*. 2016;3(8):e362-e370. doi:10.1016/S2352-3026(16)30062-X
49. Gaultney JG, Franken MG, Tan SS, et al. Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. *Journal of Clinical Pharmacy and Therapeutics*. 2013;38(1):41-47. doi:10.1111/jcpt.12020
50. EMA. EMA: Kymriah. European Medicines Agency. Published September 17, 2018. Accessed December 3, 2019. <https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah>
51. Z-Index - About. Accessed March 26, 2020. <https://www.z-index.nl/english>
52. Sorenson C, Drummond M, Kanavos P. *Ensuring Value for Money in Health Care: The Role of Health Technology Assessment in the European Union. Observatory Studies Series No 11*. World Health Organization; 2008:179.
53. Zorginstituut Nederland. Sluis voor dure geneesmiddelen. Published May 28, 2018. Accessed June 16, 2020. <https://www.zorginstituutnederland.nl/over-ons/programmas-en-samenwerkingsverbanden/horizonscan-geneesmiddelen/sluis-voor-dure-geneesmiddelen>
54. National Institute for Health and Care Excellence. *National Institute for Health and Care Excellence. Business Plan: Objectives and Performance Measures 2017 - 2018*. National Institute for Health and Care Excellence; 2017. Accessed June 30, 2020. <https://www.nice.org.uk/Media/Default/About/Who-we-are/Corporate-publications/Corporate-and-business-plans/business-plan-17-18.pdf>

55. National Institute for Health and Care Excellence. NICE technology appraisal guidance [Internet]. NICE. Published June 2020. Accessed June 30, 2020. <https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance>
56. McKinlay RJ, Wilczynski NL, Haynes RB. Optimal search strategies for detecting cost and economic studies in EMBASE. *BMC Health Services Research*. 2006;6(1):67.
57. Shemilt I, Mugford M, Vale L, Marsh K, Donaldson C, Drummond M. Evidence synthesis, economics and public policy. *Research synthesis methods*. 2010;1(2):126-135.
58. Sassi F, Archard L, McDaïd D. Searching literature databases for health care economic evaluations: how systematic can we afford to be? *Medical care*. 2002;40(5):387-394.
59. Jenkins M. Evaluation of methodological search filters—a review. *Health Information & Libraries Journal*. 2004;21(3):148-163. doi:10.1111/j.1471-1842.2004.00511.x
60. Alton V, Eckerlund I, Norlund A. Health economic evaluations: how to find them. *International journal of technology assessment in health care*. 2006;22(04):512-517.
61. McGowan J, Sampson M. Systematic reviews need systematic searchers. *Journal of the Medical Library Association*. 2005;93(1):74.
62. Higgins J, Green S. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]*. The Cochrane Collaboration; 2011. <http://www.cochrane-handbook.org>
63. Wijnen BFM, van Mastrigt GAPG, Evers SMAA, et al. A systematic review of economic evaluations of treatments for patients with epilepsy. *Epilepsia*. 2017;58(5):706-726. doi:10.1111/epi.13655
64. National Institute for Health and Care Excellence. 5 Identifying the evidence: literature searching and evidence submission. In: *Developing NICE Guidelines: The Manual*. National Institute for Health and Care Excellence; 2014. <https://www.nice.org.uk/article/pmg20/chapter/5-Identifying-the-evidence-literature-searching-and-evidence-submission>
65. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. *Canadian Medical Association Journal*. 2010;182(18):E839-E842. doi:10.1503/cmaj.090449
66. Qaseem A, Forland F, Macbeth F, Ollenschläger Gá, Phillips S, van der Wees P. Guidelines International Network: toward international standards for clinical practice guidelines. *Annals of internal medicine*. 2012;156(7):525-531.
67. National Institute for Health and Care Excellence. 7 Incorporating economic evidence. In: *Developing NICE Guidelines: The Manual*. National Institute for Health and Care Excellence; 2014. <http://www.nice.org.uk/article/PMG20/chapter/7-Incorporating-economic-evaluation>
68. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins J, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]*. The Cochrane Collaboration; 2011. www.cochrane-handbook.org
69. Rethlefsen ML, Farrell AM, Osterhaus Trzasko LC, Brigham TJ. Librarian co-authors correlated with higher quality reported search strategies in general internal medicine systematic reviews. *Journal of Clinical Epidemiology*. 6;68(6):617-626. doi:10.1016/j.jclinepi.2014.11.025
70. Wijnen B, van Mastrigt GAPG, Redekop WK, Majoie HJM, de Kinderen RJA, Evers SMAA. How to Prepare a Systematic Review of Economic Evaluations for Informing Evidence-based Healthcare Decisions: Data extraction, risk of bias, and transferability (Part 3 of 3).
71. HEED: Health Economic Evaluations Database. Accessed January 20, 2016. <http://onlinelibrary.wiley.com/book/10.1002/9780470510933>
72. Centre for Reviews Dissemination. News. Published 2016. Accessed January 20, 2016. <http://www.crd.york.ac.uk/CRDWeb/>

73. White VJ, Glanville JM, Lefebvre C, Sheldon TA. A statistical approach to designing search filters to find systematic reviews: objectivity enhances accuracy. *Journal of Information Science*. 2001;27(6):357-370. doi:10.1177/016555150102700601
74. Leshow AR, Blum RE, Berlin JA, Stoto MA, Colditz GA. Searching one or two databases was insufficient for meta-analysis of observational studies. *Journal of clinical epidemiology*. 2005;58(9):867-873.
75. Dickersin K, Scherer R, Lefebvre C. Systematic Reviews: Identifying relevant studies for systematic reviews. *BMJ*. 1994;309(6964):1286-1291. doi:10.1136/bmj.309.6964.1286
76. Brett AJ, Long AF, Grant MJ, Greenhalgh J. Searching for information on outcomes: do you need to be comprehensive? *Quality in Health Care*. 1998;7(3):163-167.
77. Morton S, Levit L, Berg A, Eden J. *Finding What Works in Health Care: Standards for Systematic Reviews*. National Academies Press; 2011.
78. Bramer WM, Giustini D, Kramer BMR. Comparing the coverage, recall, and precision of searches for 120 systematic reviews in Embase, MEDLINE, and Google Scholar: a prospective study. *Systematic Reviews*. 2016;5(1):1-7. doi:10.1186/s13643-016-0215-7
79. Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(14)-EHC063-EF. Published 2014. www.effectivehealthcare.ahrq.gov
80. Shea B, Grimshaw J, Wells G, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Medical Research Methodology*. 2007;7(1):10.
81. Halladay CW, Trikalinos TA, Schmid IT, Schmid CH, Dahabreh IJ. Using data sources beyond PubMed has a modest impact on the results of systematic reviews of therapeutic interventions. *Journal of Clinical Epidemiology*. 9;68(9):1076-1084. doi:10.1016/j.jclinepi.2014.12.017
82. Ingvild Kirkehei, Su Golder. Service providers and search interfaces. Published January 21, 2016. Accessed February 18, 2016. <http://www.htai.org/vortal/?q=node/927>
83. Fröschl B, Bornschein B, Brunner-Ziegler S, Conrads-Frank A, Eisenmann A, Gartlehner G. Methodenhandbuch für health technology assessment version 1.2012. *Gesundheit Österreich GmbH (GÖG)*. Published online 2012.
84. Glanville J, Paisley S. Identifying economic evaluations for health technology assessment. *International journal of technology assessment in health care*. 2010;26(04):436-440.
85. Akers J, Aguiar-Ibáñez R, Baba-Akbari Sari A. CRD's Guidance for Undertaking Reviews in Health Care. *York (UK): Centre for Reviews and Dissemination (CRD)*. Published online 2009.
86. Healthcare Improvement Scotland. *Standard Operating Procedure for Production of Evidence Notes (Version 2.0)*. Healthcare Improvement Scotland; 2012.
87. Healthcare Improvement Scotland. *Standard Operating Procedure for Production of Technologies Scoping Reports (Version 1.0)*. Edinburgh (Scotland). Healthcare Improvement Scotland; 2012.
88. National Health and Medical Research Council. *How to Compare the Costs and Benefits: Evaluation of the Economic Evidence*. National Health and Medical Research Council (NHMRC); 2001.
89. NHS Quality Improvement Scotland. *SIGN 50—A Guideline Developer's Handbook*. NHS Quality Improvement Scotland (NHS QIS); 2011.
90. Kristensen F, Sigmund H. *Health Technology Assessment Handbook*. Danish Centre for Health Technology Assessment (DACEHTA), National Board of Health (NBoH); 2007.
91. Cleemput I, Van den Bruel A, Kohn L, al. et. *Search for Evidence & Critical Appraisal: Health Technology Assessment (HTA)*. Belgian Federal Health Care Knowledge Centre (KCE); 2007.
92. Shemilt I, Mugford M, Byford S, et al. Incorporating economics evidence. *Cochrane handbook for systematic reviews of interventions*. Published online 2008:449-480.

93. Mathes T, Walgenbach M, Antoine S-L, Pieper D, Eikermann M. Methods for Systematic Reviews of Health Economic Evaluations A Systematic Review, Comparison, and Synthesis of Method Literature. *Medical Decision Making*. 2014;34(7):826-840.
94. Resources. Accessed February 18, 2016. <http://www.c-cemg.org/home/resources>
95. Porta MS, International Epidemiological A. A dictionary of epidemiology. In: 5th ed. / Oxford University Press; 2008. ebrary <http://site.ebrary.com/id/10375136> EBSCOhost <http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=315336> MyiLibrary <http://www.mylibrary.com?id=254360> Oxford Reference Online <http://www.oxfordreference.com/view/10.1093/acref/9780195314496.001.0001/acref-9780195314496>
96. Hopewell S, McDonald S, Clarke M, Egger M. Grey literature in meta-analyses of randomized trials of health care interventions. *Cochrane Database Syst Rev*. 2007;2(2).
97. CRD Database. Accessed August 4, 2016. <http://www.crd.york.ac.uk/CRDWeb/>
98. Science Citation Index Expanded. Accessed February 18, 2016. <http://thomsonreuters.com/en/products-services/scholarly-scientific-research/scholarly-search-and-discovery/science-citation-index-expanded.html>
99. Eady AM, Wilczynski NL, Haynes RB. PsycINFO search strategies identified methodologically sound therapy studies and review articles for use by clinicians and researchers. *Journal of Clinical Epidemiology*. 1;61(1):34-40. doi:10.1016/j.jclinepi.2006.09.016
100. Löhönen J, Isohanni M, Nieminen P, Miettunen J. Coverage of the bibliographic databases in mental health research. *Nordic journal of psychiatry*. 2010;64(3):181-188.
101. Ovid MEDLINE. Accessed February 17, 2016. gateway.ovid.com/autologin.html
102. Embase. Embase. Accessed February 17, 2016. www.embase.com
103. Econlit. Accessed August 4, 2016. <https://www.aea-web.org/econlit/index.php>
104. Web of Science. Accessed August 4, 2016. https://apps.webofknowledge.com/UA_GeneralSearch_input.do?product=UA&search_mode=GeneralSearch&SID=3AbDfUY7pV3cFFrEDlg&preferencesSaved=
105. Bramer WM, Rethlefsen ML, Mast F, Kleijnen J. Non-inferiority of the Erasmus MC exhaustive search method: An inter-organizational comparison of the speed and quality of librarian-mediated literature searches for systematic reviews. Submitted.
106. McGowan J. For expert literature searching, call a librarian. *CMAJ: Canadian Medical Association Journal*. 2001;165(10):1301-1302.
107. Bramer WM, Milic J, Mast F. Reviewing retrieved references for inclusion in systematic reviews using EndNote. *Journal of Medical Library Association*.
108. Boeker M, Motschall E, Vach W. Literature search methodology for systematic reviews: conventional and natural language processing enabled methods are complementary (Letter commenting on: J Clin Epidemiol. 2015;68:191-9). *Journal of Clinical Epidemiology*. 1;69:253-255. doi:10.1016/j.jclinepi.2015.05.022
109. Hausner E, Guddat C, Hermanns T, Lampert U, Waffenschmidt S. Development of search strategies for systematic reviews: validation showed the noninferiority of the objective approach. *Journal of Clinical Epidemiology*. 2;68(2):191-199. doi:10.1016/j.jclinepi.2014.09.016
110. Elsevier. A comparison of MeSH® and Emtree®. Published online 2015. http://supportcontent.elsevier.com/Support%20Hub/Embase/Files%20%20Attachments/4685-Embase_White%20Paper_Comparison%20of%20Emtree%20and%20MeSH_July%202015.pdf
111. Beale S, Duffy S, Glanville J, et al. Choosing and using methodological search filters: Searchers' views. *Health Information and Libraries Journal*. 2014;31(2):133-147. doi:10.1111/hir.12062
112. Haynes RB, Wilczynski N, McKibbon KA, Walker CJ, Sinclair JC. Developing Optimal Search Strategies for Detecting Clinically Sound Studies in MEDLINE. *Journal of the American Medical Informatics Association*. 1994;1(6):447-458. doi:10.1136/jamia.1994.95153434

113. Glanville J. *Development and Testing of Search Filters to Identify Economic Evaluations in MEDLINE and EMBASE*. Canadian Agency for Drugs and Technologies in Health. Agence canadienne des médicaments et des technologies de la santé; 2009.
114. Boynton J, Glanville J, McDaid D, Lefebvre C. Identifying systematic reviews in MEDLINE: developing an objective approach to search strategy design. *Journal of Information Science*. 1998;24(3):137-154.
115. Camosso-Stefinovic J. Developing Objectively Derived Search Strategies To Identify Randomized Controlled Trials in MEDLINE. *MSci thesis Loughborough: Loughborough University, Department of Information and Library Studies*. Published online 2002.
116. Bramer WM. Improving efficiency and confidence in systematic literature searching. Published 2015. Accessed June 24, 2016. <http://de.slideshare.net/wichor>
117. Russell R, Chung M, Balk EM, et al. Issues and Challenges in Conducting Systematic Reviews to Support Development of Nutrient Reference Values: Workshop Summary: Nutrition Research Series, Vol. 2. Published online 2009. <http://europepmc.org/abstract/MED/20734514> <http://www.ncbi.nlm.nih.gov/books/NBK44081> <http://europepmc.org/books/NBK44081>
118. Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. *BMC Health Services Research*. 2014;14(1):1-10. doi:10.1186/s12913-014-0579-0
119. Embase. PICO Search. Published 2016. Accessed April 7, 2016. <https://www.embase.com/#picoSearch/default>
120. Sampson M, McGowan J, Cogo E, Grimshaw J, Moher D, Lefebvre C. An evidence-based practice guideline for the peer review of electronic search strategies. *Journal of clinical epidemiology*. 2009;62(9):944-952.
121. Home. Accessed June 5, 2016. <https://www.nice.org.uk/>
122. ISSG. The InterTASC Information Specialists' Sub-Group Search Filter Resource. Published December 2, 2016. Accessed February 26, 2016. <https://sites.google.com/a/york.ac.uk/issg-search-filters-resource/home>
123. Glanville J, Kaunelis D, Mensinkai S. How well do search filters perform in identifying economic evaluations in MEDLINE and EMBASE. *International Journal of Technology Assessment in Health Care*. 2009;25(4):522-529. doi:10.1017/S0266462309990523
124. ISSG. Filters to find Economic Evaluations. Accessed January 26, 2016. <https://sites.google.com/a/york.ac.uk/issg-search-filters-resource/filters-to-find-i>
125. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. *PRESS Peer Review Electronic Search Strategies: 2015 Guideline Explanation and Elaboration (PRESS E&E)*. CADTH; 2016. https://www.cadth.ca/sites/default/files/pdf/CP0015_PRESS_Update_Report_2016.pdf
126. Wilczynski NL, Haynes RB, Lavis JN, Ramkissoonsingh R, Arnold-Oatley AE, Team THH. Optimal search strategies for detecting health services research studies in MEDLINE. *Canadian Medical Association Journal*. 2004;171(10):1179-1185. doi:10.1503/cmaj.1040512
127. Institute of Medicine of the National Academies. *Finding What Works in Health Care Standards for Systematic Reviews*. (Eden J, ed.). National Academies Press; 2011. <http://site.ebrary.com/id/10495472>
128. Sarawagi S, Bhamidipaty A. Interactive deduplication using active learning. In: ACM; 2002:269-278. doi:10.1145/775047.775087
129. Miller MC. Reference management software: a review of EndNote Plus, Reference Manager, and Pro-Cite. *MD Comput*. 1994;11(3):161-168.
130. OCLC. WorldCat. Accessed February 29, 2016. <http://www.worldcat.org/>
131. Bramer W, Holland L, Mollema J, Hannon T, Bekhuis T. Removing duplicates in retrieval sets from electronic databases: Comparing the efficiency and accuracy of the Bramer-method with other methods and software packages. Published online 2014.

132. Jiang Y, Lin C, Meng W, Yu C, Cohen AM, Smalheiser NR. Rule-based deduplication of article records from bibliographic databases. *Database*. 2014;2014:bat086.
133. Qi X, Yang M, Ren W, et al. Find duplicates among the PubMed, EMBASE, and Cochrane Library Databases in systematic review. *PLoS One*. 2013;8(8):e71838.
134. Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. Deduplication of database search results for systematic reviews in EndNote. *J Med Libr Assoc*.
135. Higgins J, Deeks JJ. Chapter 7: Selecting studies and collecting data. In: Higgins J, Deeks JJ, eds. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]*. The Cochrane Collaboration; 2011. www.cochrane-handbook.org
136. Marshall C, Brereton P. Systematic review toolbox: a catalogue of tools to support systematic reviews. In: ACM; 2015:23.
137. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *Annals of Internal Medicine*. 2009;151(4):264-269. doi:10.7326/0003-4819-151-4-200908180-00135
138. Hausner E, Waffenschmidt S. Response to letter by Boeker et al. Development of search strategies for systematic reviews: further issues regarding the objective and conceptual approaches. *Journal of Clinical Epidemiology*. 1;69:255-257. doi:10.1016/j.jclinepi.2015.05.021
139. Moher D, Tsertsvadze A. Systematic reviews: when is an update an update? *The Lancet*. 2006;367(9514):881-883.
140. Shojania KG, Sampson M, Ansari MT, Ji J, Doucette S, Moher D. How quickly do systematic reviews go out of date? A survival analysis. *Annals of internal medicine*. 2007;147(4):224-233.
141. Ahmadzai N, Newberry SJ, Maglione MA, et al. A surveillance system to assess the need for updating systematic reviews. *Systematic reviews*. 2013;2(1):1.
142. Elliott JH, Turner T, Clavisi O, et al. Living Systematic Reviews: An Emerging Opportunity to Narrow the Evidence-Practice Gap. *PLoS Med*. 2014;11(2):e1001603. doi:10.1371/journal.pmed.1001603
143. Tsertsvadze A, Chen Y-F, Moher D, Sutcliffe P, McCarthy N. How to conduct systematic reviews more expeditiously? *Systematic reviews*. 2015;4(1):1-6.
144. Elliott J, Sim I, Thomas J, et al. #CochraneTech: technology and the future of systematic reviews. *The Cochrane database of systematic reviews*. 2014;9:Ed000091. doi:10.1002/14651858.ed000091
145. Tsafnat G, Dunn A, Glasziou P, Coiera E. The automation of systematic reviews. Published online 2013.
146. Topfer L-A, Parada A, Menon D, Noorani H, Perras C, Serra-Prat M. Comparison of literature searches on quality and costs for health technology assessment using the MEDLINE and EMBASE databases. *International journal of technology assessment in health care*. 1999;15(02):297-303.
147. Sampson M, de Bruijn B, Urquhart C, Shojania K. Complementary approaches to searching MEDLINE may be sufficient for updating existing systematic reviews. *Journal of Clinical Epidemiology*. Published online 2016. doi:10.1016/j.jclinepi.2016.03.004
148. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G. *Methods for the Economic Evaluation of Health Care Programmes*. Oxford University Press; 2005.
149. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. *Methods for the Economic Evaluation of Health Care Programmes*. Oxford university press; 2015.
150. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. *PLoS Med*. 2013;10(7):e1001484.
151. Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. *The Lancet*. 2013;381(9861):142-151. doi:10.1016/S0140-6736(12)61229-X

152. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. *Blood*. 2010;115(17):3447-3452. doi:10.1182/blood-2009-07-233700
153. Gardner K, Douiri A, Drasar E, et al. Survival in adults with sickle cell disease in a high-income setting. *Blood*. 2016;128(10):1436-1438. doi:10.1182/blood-2016-05-716910
154. Peters M, Fijnvandraat K, van den Tweel XW, et al. One-third of the new paediatric patients with sickle cell disease in The Netherlands are immigrants and do not benefit from neonatal screening. *Arch Dis Child*. 2010;95(10):822-825.
155. Lobitz S, Telfer P, Cela E, et al. Newborn screening for sickle cell disease in Europe: recommendations from a Pan-European Consensus Conference. *British Journal of Haematology*. 2018;183(4):648-660. doi:10.1111/bjh.15600
156. Suijker MH, Roovers EA, Fijnvandraat CJ, et al. [Haemoglobinopathy in the 21st century: incidence, diagnosis and heel prick screening] Hemoglobinopathie in de 21e eeuw: incidentie, diagnose en hielprik-screening. *Ned Tijdschr Geneesk*. 2014;158:A7365.
157. Houwing ME, de Pagter PJ, Nur E, Fijnvandraat CJ, Cnossen MH. Routine comprehensive care for patients with sickle-cell disease in the Netherlands. *Bulletin of the Netherlands Society for tropical medicine and international health*. 2017;55(4):6-8.
158. Heijboer H; P M. Sectierichtlijn: Sikkkelcelziekte, leidraad voor de begeleiding van kinderen met sikkkelcelziekte. Published online 2016.
159. Shah N, Bhor M, Xie L, Paulose J, Yuce H. Sickle cell disease complications: Prevalence and resource utilization. *PLoS One*. 2019;14(7):e0214355.
160. Epstein K, Yuen E, Riggio JM, Ballas SK, Moleski SM. Utilization of the office, hospital and emergency department for adult sickle cell patients: a five-year study. *J Natl Med Assoc*. 2006;98(7):1109-1113.
161. Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. *Am J Hematol*. 2009;84(6):323-327.
162. Woods K, Karrison T, Koshy M, Patel A, Friedmann P, Cassel C. Hospital utilization patterns and costs for adult sickle cell patients in Illinois. *Public Health Rep*. 1997;112(1):44-51.
163. Pizzo E, Laverty AA, Phekoo KJ, et al. A retrospective analysis of the cost of hospitalizations for sickle cell disease with crisis in England, 2010/11. *J Public Health (Oxf)*. 2015;37(3):529-539.
164. Davis H, Moore RM Jr, Gergen PJ. Cost of hospitalizations associated with sickle cell disease in the United States. *Public Health Rep*. 1997;112(1):40-43.
165. Olatunya O, Ogundare E, Fadare J, et al. *The Financial Burden of Sickle Cell Disease on Households in Ekiti, Southwest Nigeria*. Vol 7.; 2015. doi:10.2147/ceor.S86599
166. Bou-Maroun LM, Meta F, Hanba CJ, Campbell AD, Yanik GA. An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomes. *Pediatr Blood Cancer*. 2018;65(1).
167. Raphael JL, Dietrich CL, Whitmire D, Mahoney DH, Mueller BU, Giardino AP. Healthcare utilization and expenditures for low income children with sickle cell disease. *Pediatr Blood Cancer*. 2009;52(2):263-267.
168. Bilenker JH, Weller WE, Shaffer TJ, Dover GJ, Anderson GF. The costs of children with sickle cell anemia: preparing for managed care. *J Pediatr Hematol Oncol*. 1998;20(6):528-533.
169. Yang YM, Shah AK, Watson M, Mankad VN. Comparison of costs to the health sector of comprehensive and episodic health care for sickle cell disease patients. *Public Health Rep*. 1995;110(1):80-86.
170. Nietert PJ, Abboud MR, Zoller JS, Silverstein MD. Costs, charges, and reimbursements for persons with sickle cell disease. *J Pediatr Hematol Oncol*. 1999;21(5):389-396.
171. Dutch Healthcare Authority (in Dutch: Nederlandse Zorgautoriteit Nz. NZa Zorgproducten Tariefapplicatie. Published 2018. Accessed January 1, 2019. <https://zorgproducten.nza.nl/>

172. Dutch Healthcare Institute (in Dutch: Zorginstituut Nederland). Medicijnkosten. Published May 2019. Accessed January 1, 2019. <https://www.medicijnkosten.nl/>
173. Dutch Healthcare Authority (in Dutch: Nederlandse Zorgautoriteit Nz. Open data van de Nederlandse Zorgautoriteit. Published 2017. Accessed January 1, 2019. <https://www.opendisdata.nl/>
174. Hakkaart-van Roijen L, van der Linden N, Bouwamans C, KanTERS T, Swan Tan S. Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. Bijlage 1.
175. NVZ (Nederlandse Vereniging van Ziekenhuizen). CAO Ziekenhuizen 2017 - 2019. Published 2019. Accessed January 11, 2019. <https://cao-ziekenhuizen.nl/cao-ziekenhuizen-2017-2019>
176. Statistics Netherlands (in Dutch: Centraal Bureau voor de Statistiek). Consumer prices 1.7 percent up in 2018. Published 2019. Accessed January 1, 2019. <https://www.cbs.nl/en-gb/news/2019/02/consumer-prices-1-7-percent-up-in-2018>
177. Zeuner D, Ades AE, Karnon J, Brown J, Dezateux C, Anionwu EN. Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis. *Health Technol Assess*. 1999;3(11):i-v, 1-186.
178. Ballas SK. The cost of health care for patients with sickle cell disease. *Am J Hematol*. 2009;84(6):320-322.
179. Serjeant GR, Serjeant BE, Mason KP, Hambleton IR, Fisher C, Higgs DR. The changing face of homozygous sickle cell disease: 102 patients over 60 years. *Int J Lab Hematol*. 2009;31(6):585-596.
180. Renoux C, Romana M, Joly P, et al. Effect of Age on Blood Rheology in Sickle Cell Anaemia and Sickle Cell Haemoglobin C Disease: A Cross-Sectional Study. *PLoS One*. 2016;11(6):e0158182.
181. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of Sickle Cell Anemia: A 4-Decade Observational Study of 1056 Patients. *Medicine*. 2005;84(6):363-376. doi:10.1097/01.md.0000189089.45003.52
182. Darbari DS, Onyekwere O, Nourae M, et al. Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia. *J Pediatr*. 2012;160(2):286-290.
183. Panepinto JA, Brousseau DC, Hillery CA, Scott JP. Variation in hospitalizations and hospital length of stay in children with vaso-occlusive crises in sickle cell disease. *Pediatr Blood Cancer*. 2005;44(2):182-186.
184. Armon K, Stephenson T, Gabriel V, et al. Determining the common medical presenting problems to an accident and emergency department. *Arch Dis Child*. 2001;84(5):390-392.
185. McDermott K, Stocks C, Freeman W. Overview of Pediatric Emergency Department Visits, 2015. In: *Healthcare Cost and Utilization Project (HCUP) Statistical Briefs*. MD: Agency for Healthcare Research and Quality; 2018.
186. Arnold SD, Jin Z, Sands S, Bhatia M, Kung AL, Satwani P. Allogeneic Hematopoietic Cell Transplantation for Children with Sickle Cell Disease Is Beneficial and Cost-Effective: A Single-Center Analysis. *Biology of Blood and Marrow Transplantation*. 2015;21(7):1258-1265. doi:10.1016/j.bbmt.2015.01.010
187. D'Souza A, Zhu X. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides. Published 2016. Accessed January 23, 2018. <http://www.cibmtr.org>
188. Nassereddine S, Rafei H, Elbahesh E, Tabbara I. Acute Graft Versus Host Disease: A Comprehensive Review. *Anticancer Research*. 2017;37(4):1547-1555.
189. Garnett C, Apperley JF, Pavlů J. Treatment and management of graft-versus-host disease: improving response and survival. *Therapeutic advances in hematology*. 2013;4(6):366-378.
190. Le Blanc K, Frasson F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. *The Lancet*. 2008;371(9624):1579-1586.
191. Deeg HJ. How I treat refractory acute GVHD. *Blood*. 2007;109(10):4119-4126.
192. Martin PJ, Rizzo JD, Wingard JR, et al. First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation*. 8;18(8):1150-1163. doi:10.1016/j.bbmt.2012.04.005

193. Kim SS. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation. *Annals of Pharmacotherapy*. 2007;41(9):1436-1444.
194. Westin JR, Saliba RM, De Lima M, et al. Steroid-refractory acute GVHD: predictors and outcomes. *Advances in hematology*. 2011;2011.
195. NHS England. *Clinical Commissioning Policy: Treatments for Graft versus Host Disease (GvHD) Following Haematopoietic Stem Cell Transplantation*. NHS England; 2018. <https://www.england.nhs.uk/wp-content/uploads/2017/03/gvhd-haematopoietic-stem-cell.pdf>
196. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. *The Lancet*. 2004;363(9419):1439-1441.
197. Hashmi S, Ahmed M, Murad MH, et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. *The Lancet Haematology*. 2016;3(1):e45-e52.
198. Munneke JM, Spruit M, Cornelissen AS, van Hoeven V, Voermans C, Hazenberg MD. The Potential of Mesenchymal Stromal Cells as Treatment for Severe Steroid-Refractory Acute Graft-Versus-Host Disease: A Critical Review of the Literature. *Transplantation*. Published online 2015.
199. Amorin B, Alegretti AP, Valim V, et al. Mesenchymal stem cell therapy and acute graft-versus-host disease: a review. *Human cell*. 2014;27(4):137-150.
200. Martin P, Uberti J, Soiffer R, et al. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. *Biology of Blood and Marrow Transplantation*. 2010;16(2):S169-S170.
201. RETHRIM. Published 2017. Accessed March 14, 2017. www.rethrim.eu
202. HOVON. HOVON 113 MSC. Published n . Accessed December 13, 2016. http://www.hovon.nl/studies/studies-per-ziektebeeld/sct.html?action=showstudie&studie_id=97&categorie_id=11
203. Gale R. Markov model of CLL transplants. *Bone marrow transplantation*. 2012;47(9):1145.
204. Chen X, Wang C, Yin J, Xu J, Wei J, Zhang Y. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. *PLOS ONE*. 2015;10(8):e0136991. doi:10.1371/journal.pone.0136991
205. Goeree R, Diaby V. Introduction to health economics and decision-making: Is economics relevant for the frontline clinician? *Best practice & research Clinical gastroenterology*. 2013;27(6):831-844. doi:10.1016/j.bpg.2013.08.016
206. Beck JR, Pauker SG. The Markov process in medical prognosis. *Medical Decision Making*. 1983;3(4):419-458.
207. Sonnenberg FA, Beck JR. Markov models in medical decision making a practical guide. *Medical decision making*. 1993;13(4):322-338.
208. Dignan FL, Clark A, Amrolia P, et al. Diagnosis and management of acute graft-versus-host disease. *British journal of haematology*. 2012;158(1):30-45.
209. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. *Transplantation*. 1974;18(4):295-304.
210. Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model a report of the ISPOR-SMDM modeling good research practices task force-2. *Medical Decision Making*. 2012;32(5):678-689.
211. Latimer N. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data. *Sheffield: Decision Support Unit*. 2013;(0).

212. Martin PJ, Counts GW, Appelbaum FR, et al. Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation. *Journal of Clinical Oncology*. 2010;28(6):1011-1016. doi:10.1200/JCO.2009.25.6693
213. Zorginstituut Nederland. Guideline for economic evaluations in healthcare. Published online 2016. <https://www.zorginstituutnederland.nl/binaries/content/documents/zinl-www/documenten/publicaties/publications-in-english/2016/1606-guideline-for-economic-evaluations-in-healthcare/Guideline+for+economic+evaluations+in+healthcare.pdf>
214. Severens JL, Milne RJ. Discounting health outcomes in economic evaluation: the ongoing debate. *Value in health*. 2004;7(4):397-401.
215. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. *Pharmacoeconomics*. 1998;13(4):397-409.
216. Briggs A, Sculpher M, Claxton K. *Decision Modelling for Health Economic Evaluation*. Oxford University Press; 2006.
217. Martin PJ, Bachier CR, Klingemann H-G, et al. Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-host Disease: A Consensus Document. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 5;15(7):777. doi:10.1016/j.bbmt.2009.03.012
218. Fang B, Song Y, Liao L, Zhang Y, Zhao R. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. In: Vol 39. Elsevier; 2007:3358-3362. http://ac.els-cdn.com/S0041134507011530/1-s2.0-S0041134507011530-main.pdf?_tid=d8a7151e-d359-11e6-a6f6-00000aabb0f26&acdnat=1483629532_9c95b1be5493e3533c4feb95ee415912
219. Von Bonin M, Stölzel F, Goedecke A, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. *Bone marrow transplantation*. 2009;43(3):245-251.
220. Müller I, Kordowich S, Holzwarth C, et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. *Blood Cells, Molecules, and Diseases*. 2008;40(1):25-32.
221. Prasad VK, Lucas KG, Kleiner GI, et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. *Biology of Blood and Marrow Transplantation*. 2011;17(4):534-541.
222. Pérez-Simon JA, Lopez-Villar O, Andreu EJ, et al. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. *Haematologica*. 2011;96(7):1072-1076.
223. Herrmann R, Sturm M, Shaw K, et al. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study. *International journal of hematology*. 2012;95(2):182-188.
224. Chen G, Yang T, Qiao M, Miao M, Wu D. Clinical study of umbilical cord-derived mesenchymal stem cell for treatment of nineteen patients with steroid-resistant severe acute graft-versus-host disease. *Cytotherapy*. 2014;16(4):S34.
225. Muroi K, Miyamura K, Ohashi K, et al. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study. *International journal of hematology*. 2013;98(2):206-213.
226. Resnick IB, Barkats C, Shapira MY, et al. Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). *Am J Blood Res*. 2013;3(3):225-238.
227. Ball LM, Bernardo ME, Roelofs H, et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III–IV acute graft-versus-host disease. *British journal of haematology*. 2013;163(4):501-509.

228. Introna M, Lucchini G, Dander E, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. *Biology of Blood and Marrow Transplantation*. 2014;20(3):375-381.
229. Ringdén O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. *Transplantation*. 2006;81(10):1390-1397.
230. Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, et al. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. *Biology of Blood and Marrow Transplantation*. 2014;20(10):1580-1585.
231. Zhao K, Lou R, Huang F, et al. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation. *Biology of Blood and Marrow Transplantation*. 2015;21(1):97-104.
232. Te Boome L, Mansilla C, Van Der Wagen L, et al. Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells. *Leukemia*. Published online 2015.
233. Lucchini G, Introna M, Dander E, et al. Platelet-lysate-Expanded Mesenchymal Stromal Cells as a Salvage Therapy for Severe Resistant Graft-versus-Host Disease in a Pediatric Population. *Biology of Blood and Marrow Transplantation*. 2010;16(9):1293-1301. doi:10.1016/j.bbmt.2010.03.017
234. Kurtzberg J, Prockop S, Teira P, et al. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. *Biology of Blood and Marrow Transplantation*. 2014;20(2):229-235.
235. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. *Blood*. 1991;77(8):1821-1828.
236. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. *Blood*. 1990;75(4):1024-1030.
237. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. *Blood*. 1990;76(8):1464-1472.
238. Greinix H, Knobler R, Worel N, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. *Haematologica*. 2006;91(3):405-408.
239. Ho VT, Zahrieh D, Hochberg E, et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. *Blood*. 2004;104(4):1224-1226.
240. Jacobsohn DA, Hallick J, Anders V, McMillan S, Morris L, Vogelsang GB. Infliximab for steroid-refractory acute GVHD: A case series. *American journal of hematology*. 2003;74(2):119-124.
241. Remberger M, Ringdén O. Treatment of severe acute graft-versus-host disease with mesenchymal stromal cells: a comparison with non-MSC treated patients. *International Journal of Hematology*. 2012;96(6):822-824. doi:10.1007/s12185-012-1218-3
242. von Bahr L, Sundberg B, Lönnies L, et al. Long-Term Complications, Immunologic Effects, and Role of Passage for Outcome in Mesenchymal Stromal Cell Therapy. *Biology of Blood and Marrow Transplantation*. 2012;18(4):557-564. doi:10.1016/j.bbmt.2011.07.023
243. Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. *Lancet*. 2010;376(9757):2009-2017. doi:10.1016/S0140-6736(10)62002-8
244. Gore L, Locatelli F, Zugmaier G, et al. Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. *Blood Cancer J*. 2018;8(9). doi:10.1038/s41408-018-0117-0

245. Stackelberg A von, Locatelli F, Zugmaier G, et al. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology*. Published online October 3, 2016. doi:10.1200/JCO.2016.67.3301
246. Maude SL, Teachey DT, Rheingold SR, et al. Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. *JCO*. 2016;34(15_suppl):3011-3011. doi:10.1200/JCO.2016.34.15_suppl.3011
247. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. *N Engl J Med*. 2018;378(5):439-448. doi:10.1056/NEJMoa1709866
248. Maude SL, Frey N, Shaw PA, et al. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. *N Engl J Med*. 2014;371(16):1507-1517. doi:10.1056/NEJMoa1407222
249. Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. *Blood*. 2017;129(25):3322-3331. doi:10.1182/blood-2017-02-769208
250. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. *The Lancet*. 2015;385(9967):517-528. doi:10.1016/S0140-6736(14)61403-3
251. Forsberg MH, Das A, Saha K, Capitini CM. The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL. *Therapeutics and clinical risk management*. 2018;14:1573-1584. doi:10.2147/TCRM.S146309
252. National Institute for Health and Care Excellence. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. Published 2018. Accessed March 11, 2020. <https://www.nice.org.uk/guidance/ta554/chapter/2-Information-about-tisagenlecleucel>
253. Whittington MD, McQueen RB, Campbell JD. Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies. *JAMA Pediatrics*. 2018;172(5):409. doi:10.1001/jamapediatrics.2018.0049
254. Sarkar R, Gloude NJ, Murphy JD. Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed/refractory acute lymphoblastic leukemia. *Journal of Clinical Oncology*. 2018;36(15). doi:10.1200/JCO.2018.36.15-suppl.6610
255. Lin JK, Barnes J, Lerman BJ, et al. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia. *Article in Journal of Clinical Oncology*. 2018;36. doi:10.1200/JCO.2018.79.0642
256. CADTH. *Tisagenlecleucel for Acute Lymphoblastic Leukemia: Economic Review Report*. Canadian Agency for Drugs and Technologies in Health (CADTH); 2019:61.
257. Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients with Relapsed or Refractory Leukemia. *JAMA Pediatrics*. 2018;172(12):1161-1168. doi:10.1001/jamapediatrics.2018.2530
258. Walton M, Sharif S, Simmonds M, Claxton L, Hodgson R. Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. *Pharmacoeconomics*. Published online April 13, 2019. doi:10.1007/s40273-019-00799-0
259. Kellerborg K, Perry-Duxbury M, de Vries L, van Baal P. Practical Guidance for Including Future Costs in Economic Evaluations. *[Not yet published]*.
260. van Baal PHM, Wong A, Slobbe LCJ, Polder JJ, Brouwer WBF, de Wit GA. Standardizing the Inclusion of Indirect Medical Costs in Economic Evaluations. *Pharmacoeconomics*. 2011;29(3):175-187. doi:10.2165/11586130-000000000-00000

261. Royston P, Parmar MKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. *Statistics in Medicine*. 2002;21(15):2175-2197. doi:10.1002/sim.1203
262. ClinicalTrials.gov. Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL and High Risk B-cell ALL at First Relapse. Determine Feasibility and Safety of CTL019 Therapy in Pediatric Patients With High Risk B-cell ALL That Relapsed < 6 Months Post All-HSCT. (ELIANA). Accessed March 16, 2020. <https://clinicaltrials.gov/ct2/show/NCT02435849>
263. ClinicalTrials.gov. Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients. Accessed March 16, 2020. <https://clinicaltrials.gov/ct2/show/NCT02228096>
264. ClinicalTrials.gov. Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma. Accessed March 16, 2020. <https://clinicaltrials.gov/ct2/show/NCT01626495>
265. Evoltra (Clofarabine, Sanofi). Summary of product characteristics. Accessed March 16, 2020. https://www.ema.europa.eu/en/documents/product-information/evoltra-epar-product-information_en.pdf
266. Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. *Blood*. 2011;118(23):6043-6049. doi:10.1182/blood-2011-08-374710
267. Berg H van den, Groot-Kruseman HA de, Damen-Korbijn CM, Bont ESJM de, Meeteren AYNS, Hoogerbrugge PM. Outcome after first relapse in children with acute lymphoblastic leukemia: A report based on the Dutch Childhood Oncology Group (DCOG) relapse all 98 protocol. *Pediatric Blood & Cancer*. 2011;57(2):210-216. doi:10.1002/pbc.22946
268. Armstrong GT, Chen Y, Yasui Y, et al. Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. *New England Journal of Medicine*. 2016;374(9):833-842. doi:10.1056/NEJMoa1510795
269. Attema AE, Brouwer WBF, Claxton K. Discounting in Economic Evaluations. *Pharmacoeconomics*. 2018;36(7):745-758. doi:10.1007/s40273-018-0672-z
270. Jha S, Gaynon PS, Razzouk BI, et al. Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia. *JCO*. 2006;24(12):1917-1923. doi:10.1200/JCO.2005.03.8554
271. Lamers LM, McDonnell J, Stalmeier PFM, Krabbe PFM, Busschbach JJV. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. *Health Economics*. 2006;15(10):1121-1132. doi:10.1002/hec.1124
272. Forsythe A, Brandt PS, Dolph M, Patel S, Rabe APJ, Tremblay G. Systematic review of health state utility values for acute myeloid leukemia. *Clinicoecon Outcomes Res*. 2018;10:83-92. doi:10.2147/CEOR.S153286
273. Kwon J, Kim SW, Ungar WJ, Tsiplova K, Madan J, Petrou S. A Systematic Review and Meta-analysis of Childhood Health Utilities. *Med Decis Making*. 2018;38(3):277-305. doi:10.1177/0272989X17732990
274. Janssen B, Szende A. Population Norms for the EQ-5D. In: Szende A, Janssen B, Cabases J, eds. *Self-Reported Population Health: An International Perspective Based on EQ-5D*. ; 2014. doi:10.1007/978-94-007-7596-1
275. Franken MG, Kanters TA, Coenen JL, et al. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands. *Anti-Cancer Drugs*. 2018;29(8):791-801. doi:10.1097/CAD.0000000000000648
276. PAID [version 3.0]. iMTA. Accessed March 26, 2020. <https://www.imta.nl/paid/>
277. Langeveld NE, Ubbink MC, Last BF, Grootenhuis MA, VoÛte PA, Haan RJ de. Educational achievement, employment and living situation in long-term young adult survivors of childhood cancer in the Netherlands. *Psycho-Oncology*. 2003;12(3):213-225. doi:10.1002/pon.628

278. Gaynon PS, Harris RE, Altman AJ, et al. Bone Marrow Transplantation Versus Prolonged Intensive Chemotherapy for Children With Acute Lymphoblastic Leukemia and an Initial Bone Marrow Relapse Within 12 Months of the Completion of Primary Therapy: Children's Oncology Group Study CCG-1941. *JCO*. 2006;24(19):3150-3156. doi:10.1200/JCO.2005.04.5856
279. Doorduyn JK, Buijt I, van der Holt B, van Agthoven M, Sonneveld P, Uyl-de Groot CA. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. *Haematologica*. 2004;89(9):1109-1117.
280. Schlenk RF, Döhner H, Döhner K, et al. Event-Free Survival Is a Surrogate for Overall Survival in Patients Treated for Acute Myeloid Leukemia. *Blood*. 2015;126(23):3744-3744. doi:10.1182/blood.V126.23.3744.3744
281. Keegan THM, Parsons HM. Adolescent angst: enrollment on clinical trials. *Hematology Am Soc Hematol Educ Program*. 2018;2018(1):154-160. doi:10.1182/asheducation-2018.1.154
282. Weiss AR, Hayes-Lattin B, Kutny MA, Stock W, Stegenga K, Freyer DR. Inclusion of Adolescents and Young Adults in Cancer Clinical Trials. *Semin Oncol Nurs*. 2015;31(3):197-205. doi:10.1016/j.soncn.2015.05.001
283. Sullivan SM, Tsiplova K, Ungar WJ. A scoping review of pediatric economic evaluation 1980-2014: do trends over time reflect changing priorities in evaluation methods and childhood disease? *Expert Rev Pharmacoecon Outcomes Res*. 2016;16(5):599-607. doi:10.1080/14737167.2016.1240618
284. Roth ME, O'Mara AM, Seibel NL, et al. Low Enrollment of Adolescents and Young Adults Onto Cancer Trials: Insights From the Community Clinical Oncology Program. *J Oncol Pract*. 2016;12(4):e388-e395. doi:10.1200/JOP.2015.009084
285. Kromm SK, Bethell J, Kraglund F, et al. Characteristics and quality of pediatric cost-utility analyses. *Qual Life Res*. 2012;21(8):1315-1325. doi:10.1007/s11136-011-0049-7
286. Krol M, Brouwer W, Rutten F. Productivity Costs in Economic Evaluations: Past, Present, Future. *PharmacoEconomics*. 2013;31(7):537-549. doi:10.1007/s40273-013-0056-3
287. Carias C, Chesson HW, Grosse SD, et al. Recommendations of the Second Panel on Cost Effectiveness in Health and Medicine: A Reference, Not a Rule Book. *Am J Prev Med*. 2018;54(4):600-602. doi:10.1016/j.amepre.2017.11.013
288. Freedman A. Follicular lymphoma: 2018 update on diagnosis and management. *American Journal of Hematology*. 2018;93(2):296-305. doi:10.1002/ajh.24937
289. Dinnessen M, Brink M, Korf-van Vliet C, et al. *Het Folliculair Lymfoom in Nederland, 2014-2016. Landelijk Rapport van Het Hematooncologieregister van de Nederlandse Kankerregistratie*; 2019. Accessed April 21, 2020. https://www.iknl.nl/getmedia/6fbcaf47-2677-4b4e-933d-68d5be07773b/Hematologische_kankersoorten_landelijk_rapport_iknl_FL_2014_2016.pdf
290. Kharchenko EV, Sweetenham JW. Advances in relapsed/refractory follicular lymphoma therapeutics. *ADVANCES IN CELL AND GENE THERAPY*. 2020;3(1):e74. doi:10.1002/acg2.74
291. Anonymous. MabThera. European Medicines Agency. Published September 17, 2018. Accessed March 29, 2020. <https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera>
292. Anonymous. IntronA. European Medicines Agency. Published September 17, 2018. Accessed March 29, 2020. <https://www.ema.europa.eu/en/medicines/human/EPAR/introna>
293. Anonymous. Zevalin. European Medicines Agency. Published September 17, 2018. Accessed March 30, 2020. <https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin>
294. Anonymous. Gazyvaro. European Medicines Agency. Published September 17, 2018. Accessed March 30, 2020. <https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro>
295. Anonymous. Zydelig. European Medicines Agency. Published September 17, 2018. Accessed March 30, 2020. <https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig>

296. European Medicines Agency. EMA/225905/2019. Revlimid (lenalidomide). Accessed December 2, 2019. https://www.ema.europa.eu/en/documents/overview/revlimid-epar-medicine-overview_en.pdf
297. Leonard JP, Trnėny M, Izutsu K, et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. Published online March 21, 2019;JCO1900010. doi:10.1200/JCO.19.00010
298. Fayers P, Bottomley A, on behalf of the EORTC Quality of Life Group and of the Quality of Life Unit. Quality of life research within the EORTC—the EORTC QLQ-C30. *European Journal of Cancer*. 2002;38:125-133. doi:10.1016/S0959-8049(01)00448-8
299. Rabin R, Charro F de. EQ-5D: a measure of health status from the EuroQol Group. *Annals of Medicine*. 2001;33(5):337-343. doi:10.3109/07853890109002087
300. Leonard JP, Trnėny M, Izutsu K, et al. Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (r/r) Indolent NHL in the Phase 3 AUGMENT Trial of Rituximab (R) plus Lenalidomide (R 2) versus R plus Placebo. *Hematological Oncology*. 2019;37:232-234. doi:10.1002/hon.45_2630
301. Dhanasiri S. Response to: Olry de Labry Lima A et al., Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant hematopoietic progenitor cells. *Bone Marrow Transplantation*. Published online November 21, 2019;1-2. doi:10.1038/s41409-019-0749-0
302. Brouwer WBF, van Exel NJA, Baltussen RMPM, Rutten FFH. A Dollar Is a Dollar Is a Dollar—or Is It? *Value in Health*. 2006;9(5):341-347. doi:10.1111/j.1524-4733.2006.00123.x
303. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. *J Health Econ*. 1997;16(1):33-64. doi:10.1016/s0167-6296(96)00507-3
304. Feenstra TL, van Baal PHM, Gandjour A, Brouwer WBF. Future costs in economic evaluation: A comment on Lee. *Journal of Health Economics*. 2008;27(6):1645-1649. doi:10.1016/j.jhealeco.2008.07.007
305. Woods B, Sideris E, Palmer S, Latimer N, Soares M. Partitioned Survival Analysis For Decision Modelling in Health Care: a Critical Review Report. *NICE Decision Support Unit*. 2017;(June):1-72.
306. Latimer NR. Survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. *Med Decis Making*. 2013;33(6):743-754. doi:10.1177/0272989X12472398
307. Bouwmans C, Janssen J, Huijgens P, Uyl-de Groot C. Costs of haematological adverse events in chronic myeloid leukaemia patients: a retrospective cost analysis of the treatment of anaemia, neutropenia and thrombocytopenia in patients with chronic myeloid leukaemia. *Journal of Medical Economics*. 2009;12(2):164-169. doi:10.3111/13696990903149479
308. Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. *Health Qual Life Outcomes*. 2008;6:84. doi:10.1186/1477-7525-6-84
309. Swinburn P, Lloyd A, Nathan P, Choueiri TK, Cella D, Neary MP. Elicitation of health state utilities in metastatic renal cell carcinoma. *Current Medical Research and Opinion*. 2010;26(5):1091-1096. doi:10.1185/03007991003712258
310. Nederlandse Vereniging voor Hematologie. Richtlijn voor de diagnostiek, behandeling en follow-up van het folliculair lymfoom. Published 2020. Accessed February 19, 2020. http://www.hovon.nl/upload/File/Richtlijnen_BehAdv/FL%20richtlijn_revisie2019.pdf
311. Hakkaart-van Roijen L, van der Linden N, Bouwmans C, Kanter T, Swan Tan S. Bijlage 1. Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. <https://www.zorginstituutnederland.nl/publicaties/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg>

312. Statistics Netherlands. Open data. Statistics Netherlands. Accessed March 27, 2020. <https://www.cbs.nl/en-gb/our-services/open-data>
313. The iMTA Disease Burden Calculator [version 1.3 beta]. www.imta.nl/idbc
314. Zorginstituut Nederland. *Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg*; 2016. Accessed March 11, 2020. <https://www.zorginstituutnederland.nl/publicaties/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg>
315. Arboe B, Olsen MH, Goerloe JS, et al. Return to work for patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation. *Clinical epidemiology*. 2017;9:321-329. doi:10.2147/CLEPS134603
316. *Single Technology Appraisal. Lenalidomide for Treated Follicular Lymphoma and Marginal Zone Lymphoma [ID1374]. Committee Papers*. National Institute for Health and Care Excellence; 2020. Accessed March 30, 2020. <https://www.nice.org.uk/guidance/gid-ta10323/documents/committee-papers>
317. *Final Appraisal Document. Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma*. National Institute for Health and Care Excellence; 2020. Accessed March 30, 2020. <https://www.nice.org.uk/guidance/gid-ta10323/documents/final-appraisal-determination-document>
318. Zhang P-F, Xie D, Wen F, Li Q. Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost-effectiveness analysis. *Cancer Medicine*. n/a(n/a). doi:10.1002/cam4.3121
319. Wild D, Walker M, Pettengell R, Lewis G. PCN62 Utility Elicitation in Patients with Follicular Lymphoma. *Value in Health*. 2006;9(6):A294. doi:10.1016/S1098-3015(10)63491-2
320. Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. *New England Journal of Medicine*. 2018;379(10):934-947. doi:10.1056/NEJMoa1805104
321. van Rijn M. Regeling van de Minister voor Medische Zorg van 18 mei 2020, kenmerk 1687653-205139-Z, houdende wijziging van de Regeling zorgverzekering in verband met de opname van het geneesmiddel lenalidomide in het basispakket. *Staatscourant*. 2020;(27988).
322. National Institute for Health and Care Excellence. NICE technology appraisal guidance [Internet]. Published July 2017. <https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance>
323. National Institute for Health and Care Excellence. Obinutuzumab for untreated advanced follicular lymphoma [Internet]. Published April 2018. <https://www.nice.org.uk/guidance/ta513>
324. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. *The Lancet*. 2012;380(9844):848-857. doi:10.1016/S0140-6736(12)60605-9
325. Ninkovic S, Lambert J. Non-Hodgkin lymphoma. *Medicine*. 2017;45(5):297-304. doi:10.1016/j.mpmed.2017.02.008
326. Freedman A. Follicular lymphoma: 2015 update on diagnosis and management. *American journal of hematology*. 2015;90(12):1171-1178.
327. Haematological Malignancy Research Network (HMRN). Incidence: Follicular lymphoma [Internet]. Published n. <https://www.hmrn.org/statistics/incidence>
328. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. *Blood*. Published online 2004.
329. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. *J Clin Oncol*. 2009;27(27):4555-4562. doi:10.1200/JCO.2008.21.3991
330. Nastoupil LJ, Sinha R, Byrtek M, et al. Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. *Leuk Lymphoma*. 2015;56(5):1295-1302. doi:10.3109/10428194.2014.953144

331. Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. *J Clin Oncol*. 2015;33(23):2516-2522. doi:10.1200/JCO.2014.59.7534
332. European Medicines Agency. CHMP summary of positive opinion for Gazyvaro [sic]. Published April 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002799/WC500167332.pdf
333. European Medicines Agency. CHMP post-authorisation summary of positive opinion for Gazyvaro. Published April 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/002799/WC500205392.pdf
334. European Medicines Agency. CHMP post-authorisation summary of positive opinion for Gazyvaro (II-16). Published April 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/002799/WC500231836.pdf
335. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. *New England Journal of Medicine*. 2017;377(14):1331-1344. doi:10.1056/NEJMoa1614598
336. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. *Lancet*. 2011;377(9759):42-51. doi:10.1016/S0140-6736(10)62175-7
337. Salles GA, Seymour JF, Feugier P, et al. Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. Abstract presented at the 55th Annual Meeting of the American Society of Hematology (ASH); 7-10 Dec 2013; New Orleans: US. *Blood*. 2013;122(21):no pagination.
338. Haematological Malignancy Research Network. *Patient's Age and Treatment for Haematological Malignancy: A Report from the Haematological Malignancy Research Network (HMRN) [Online PDF]*. HMRN; 2014:39. <https://www.hmrn.org/Download.aspx?target=document&cid=41>
339. Maurer MJ, Bachy E, Ghesquieres H, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. *Am J Hematol*. 2016;91(11):1096-1101. doi:10.1002/ajh.24492
340. Wild D, Walker M, Pettengell R, Lewis G. Utility elicitation in patients with follicular lymphoma (PCN62). *VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH*. 2006;9:A294.
341. Joint Formulary Committee. *British National Formulary [Internet]*. BMJ Group and Pharmaceutical Press; 2017. <https://www.medicinescomplete.com/mc/bnf/current/>
342. Department of Health. Drugs and pharmaceutical electronic market information (eMit) [Internet]. Published March 2016. <https://www.gov.uk/government/publications/drugs-and-pharmaceutical-electronic-market-information-emit>
343. National Institute for Health and Care Excellence. *Guide to the Methods of Technology Appraisal 2013 [Internet]*. NICE; 2013:93. <https://www.nice.org.uk/process/pmg9/chapter/foreword>
344. National Institute for Health and Care Excellence. *Single Technology Appraisal. Obinutuzumab for Untreated Advanced Follicular Lymphoma: Final Scope (Appendix B) [Internet]*. NICE; 2017:4. <https://www.nice.org.uk/guidance/gid-ta10137/documents/final-scope>
345. Büyükkaramikli NC, Blommestein HM, Riemsma R, et al. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. *Pharmacoeconomics*. 2017;35(12):1211-1221. doi:10.1007/s40273-017-0528-y
346. Büyükkaramikli NC, de Groot S, Fayter D, et al. Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence

- Review Group Perspective of an NICE Single Technology Appraisal. *PharmacoEconomics*. 2018;36(2):145-159. doi:10.1007/s40273-017-0581-6
347. Kaltenthaler E, Carroll C, Hill-McManus D, et al. The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis. *Health Technol Assess*. 2016;20(26):1-48. doi:10.3310/hta20260
 348. Büyükkaramikli NC, de Groot S, Riemsma R, et al. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. *Pharmacoeconomics*. 2019;37(2):141-153. doi:10.1007/s40273-018-0708-4
 349. Roche Products Limited. Annex I Summary of product characteristics. In: *EMA Document Library*. Roche Products Limited; 2018. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002799/WC500171594.pdf
 350. National Institute for Health and Care Excellence. Prescribed Services CQUIN Scheme: GE3 Hospital Medicines Optimisation [Internet]. Published July 2018. <https://www.england.nhs.uk/publication/ge3-hospital-medicines-optimisation/>
 351. O'Neill P, Devlin NJ. An analysis of NICE's "restricted" (or 'optimized') decisions. *PharmacoEconomics*. 2010;28(11):987-993. doi:10.2165/11536970-000000000-00000
 352. Dickson R, Boland A, Duarte R, et al. EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties. *Applied Health Economics and Health Policy*. 2018;16(4):429-432. doi:10.1007/s40258-018-0393-7
 353. Jürgens B, Clarke NS. Evolution of CAR T-cell immunotherapy in terms of patenting activity. *Nat Biotechnol*. 2019;37(4):370-375. doi:10.1038/s41587-019-0083-5
 354. Charrot S, Hallam S. CAR-T Cells: Future Perspectives. *HemaSphere*. 2019;3(2):e188. doi:10.1097/hs9.0000000000000188
 355. eurostat. People in the EU - population projections. [Internet].
 356. European Commission. European Cancer Information System. Estimates of cancer incidence and mortality in 2018, for all countries. [Internet].
 357. GCO, IARC. Globocan. Cancer tomorrow. Accessed December 3, 2019. <http://gco.iarc.fr/tomorrow/home>
 358. American Cancer Society. *Cancer Facts & Figures 2019*. American Cancer Society; 2019:76.
 359. Cerhan JR. Epidemiology of Follicular Lymphoma. *Hematology/Oncology Clinics of North America*. 2020;34(4):631-646. doi:10.1016/j.hoc.2020.02.001
 360. Sandoval-Sus JD, Sotomayor EM, Shah BD. Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine. *Hematology/Oncology and Stem Cell Therapy*. 2017;10(3):99-115. doi:10.1016/j.hemonc.2017.02.003
 361. Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. *Pathology*. 2018;50(1):74-87. doi:https://doi.org/10.1016/j.pathol.2017.09.006
 362. Hakkaart-van Roijen L, van der Linden N, Bouwamans C, Kanters T, Swan Tan S. Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijs voor economische evaluaties in de gezondheidszorg. Bijlage 1.
 363. Weycker D, Danel A, Marciniak A, Bendall K, Lipsitz M, Pettengell R. Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice. *BMC Cancer*. 2012;12(1):362. doi:10.1186/1471-2407-12-362
 364. Bock J-O, Brettschneider C, Seidl H, et al. Ermittlung standardisierter Bewertungssätze aus gesellschaftlicher Perspektive für die gesundheitsökonomische Evaluation. *Gesundheitswesen*. 2014;77(01):53-61. doi:10.1055/s-0034-1374621

365. Högy B, Keinecke H-O, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. *Eur J Health Econ.* 2005;6(1):24-29. doi:10.1007/s10198-004-0250-5
366. Lefrant J-Y, Garrigues B, Pribil C, et al. The daily cost of ICU patients: A micro-costing study in 23 French Intensive Care Units. *Anaesthesia Critical Care & Pain Medicine.* 2015;34(3):151-157. doi:10.1016/j.accpm.2014.09.004
367. Tan S, Martin J, Pezzi A, et al. Microcosting study of ICU costs in three European countries. *Critical Care.* 2008;12(2):P526. doi:10.1186/cc6747
368. Quinn C, Young C, Thomas J, Trusheim M. Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System. *Value in Health.* 22(6):621-626. doi:10.1016/j.jval.2019.03.014
369. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. *Tisagenlecleucel (Akute Lymphatische B-ZellLeukämie). Bewertung Gemäß § 35a Abs. 1 Satz 11 SGB V. Nr. 689;* 2018.
370. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. *Tisagenlecleucel (Diffuses Großzelliges B-ZellLymphom). Bewertung Gemäß § 35a Abs. 1 Satz 11 SGB V. Nr. 689;* 2018.
371. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. *Axicabtagene-Ciloleucel (Primär Mediatinales Großzelliges B-Zell-Lymphom) – Bewertung Gemäß § 35a Abs. 1 Satz 11 SGB V. Nr. 716;* 2019.
372. Haute Autorité de santé. Kymriah® (Tisagenlecleucel) Lymphome diffus à grandes cellules B [Internet].
373. Haute Autorité de santé. Kymriah® (Tisagenlecleucel) Leucémie aigue lymphoblastique [Internet].
374. Haute Autorité de santé. YESCARTA® (axicabtagene ciloleucel) Lymphomes diffus à grandes cellules B (LDGCB) et lymphome médiastinal primitif à grandes cellules B (LMPGCB) réfractaire ou en rechute, après au moins deux lignes de traitement systémique. [Internet].
375. National Institute for Health and Care Excellence. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. Committee papers. [Internet].
376. National Institute for Health and Care Excellence. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies. Appraisal consultation committee papers. [Internet].
377. National Institute for Health and Care Excellence. Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies. [Internet].
378. ZiN. *Pakketadvies Axicabtagene Ciloleucel (Yescarta®).* Zorginstituut Nederland; 2019.
379. ZiN. *Pakketadvies Tisagenlecleucel (Kymriah®) [DLBCL];* 2019.
380. ZiN. *Pakketadvies Tisagenlecleucel (Kymriah®) [PALL];* 2019.
381. AIFA. AIFA approva la rimborsabilità della prima terapia CAR-T. Accessed December 3, 2019. <https://www.aifa.gov.it/-/aifa-approva-la-rimborsabilita-della-prima-terapia-car-t>
382. AIFA. *Regime Di Rimborsabilità e Prezzo Del Medicinale per Uso Umano «Yescarta».* Agenzia Italiana del Farmaco; 2019. Accessed December 3, 2019. https://www.aifa.gov.it/documents/20142/961234/Determina_DG-1643-2019_Yescarta.pdf/26464c52-5e7b-e97d-74d5-f66f69039fa0
383. Secretaria general de sanidad y consumo. Nota Informativa de la Reunión de la Comisión Interministerial de Precios de los Medicamentos. Sesión 187 de 30 de Noviembre de 2018. Published 2018. https://www.msbs.gob.es/profesionales/farmacia/pdf/NOTA_INFORMATIVA_DE_LA_CIPM_187_web.pdf
384. Secretaria general de sanidad y consumo. Nota Informativa de la Reunión de la Comisión Interministerial de Precios de los Medicamentos. Sesión 189 de 18 de Marzo de 2019. Published 2019. https://www.msbs.gob.es/profesionales/farmacia/pdf/NOTA_INFORMATIVA_DE_LA_CIPM_189_web.pdf
385. Lin JK, Lerman BJ, Barnes JL, et al. Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. *Journal of Clinical Oncology.* 2018;36(32):3192-3202. doi:10.1200/JCO.2018.79.0642

386. Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients with Relapsed or Refractory Leukemia. *JAMA Pediatrics*. 2018;172(12):1161-1168. doi:10.1001/jamapediatrics.2018.2530
387. Sarkar R, Gloude NJ, Murphy JD. Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed/refractory acute lymphoblastic leukemia. *Journal of Clinical Oncology*. 2018;36(15). doi:10.1200/JCO.2018.36.15-suppl.6610
388. Walton M, Sharif S, Simmonds M, Claxton L, Hodgson R. Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. *PharmacoEconomics*. Published online April 13, 2019. doi:10.1007/s40273-019-00799-0
389. Furzer J, Gupta S, Nathan PC, et al. Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada. *JAMA Oncol*. 2020;6(3):393-401. doi:10.1001/jamaoncol.2019.5909
390. Thielen FW, Dongen-Leunis A van, Arons AMM, Ladestein JR, Hoogerbrugge PM, Uyl-de Groot CA. Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view. *European Journal of Haematology*. 2020;105(2):203-215. doi:10.1111/ejh.13427
391. Roth JA, Sullivan SD, Lin VW, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. *Journal of Medical Economics*. 2018;21(12):1238-1245. doi:10.1080/13696998.2018.1529674
392. Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma. *JAMA Network Open*. 2019;2(2):e190035-e190035. doi:10.1001/jamanetworkopen.2019.0035
393. Institute for Clinical and Economic Review. *Chimeric Antigen Receptor T-Cell Therapy for BCell Cancers: Effectiveness and Value. Final Evidence Report*; 2018.
394. CADTH. *Tisagenlecleucel for Acute Lymphoblastic Leukemia: Economic Review Report*. Canadian Agency for Drugs and Technologies in Health (CADTH); 2019:61.
395. Hettle R, Corbett M, Hinde S, et al. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. *Health technology assessment (Winchester, England)*. 2017;21(7):1-204. doi:10.3310/hta21070
396. Thielen FW, Dongen-Leunis A van, Arons AMM, Ladestein JR, Hoogerbrugge PM, Groot CU. Cost-Effectiveness of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-cell acute Lymphoblastic Leukemia. *European Journal of Haematology*. n/a(n/a). doi:10.1111/ejh.13427
397. Lin JK, Muffy LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. *JCO*. 2019;37(24):2105-2119. doi:10.1200/JCO.18.02079
398. SEER. Acute Lymphocytic Leukemia - Cancer Stat Facts. SEER. Published 2019. Accessed December 3, 2019. <https://seer.cancer.gov/statfacts/html/aly1.html>
399. Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. *Pathology*. 2018;50(1):74-87. doi:10.1016/j.pathol.2017.09.006
400. Jeremy S. Abramson, Leo I. Gordon, Maria Lia Palomba, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. *Journal of Clinical Oncology*. 2018;36(15_suppl):7505-7505. doi:10.1200/JCO.2018.36.15_suppl.7505

401. Makita S, Imaizumi K, Kurosawa S, Tobinai K. Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges. *Drugs Context*. 2019;8:212567-212567. doi:10.7573/dic.212567
402. Meghan Luchi KC. *Placing Your CAR-T Bets*. The Boston Consulting Group; 2018:7.
403. Pfeiffer A, Thalheimer FB, Hartmann S, et al. In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome. *EMBO Mol Med*. 2018;10(11). doi:10.15252/emmm.201809158
404. Abou-El-Enein M, Elsanhoury A, Reinke P. Overcoming Challenges Facing Advanced Therapies in the EU Market. *Cell Stem Cell*. 2016;19(3):293-297. doi:10.1016/j.stem.2016.08.012
405. Orkin SH, Reilly P. Paying for future success in gene therapy. *Science*. 2016;352(6289):1059-1061. doi:10.1126/science.aaf4770
406. AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families. Novartis. Accessed March 2, 2020. <https://www.novartis.com/news/media-releases/avexis-announces-innovative-zolgensma-gene-therapy-access-programs-us-payers-and-families>
407. Jørgensen J, Hanna E, Kefalas P. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries. *J Mark Access Health Policy*. 2020;8(1). doi:10.1080/20016689.2020.1715536
408. Quinn C, Young C, Thomas J, Trusheim M. Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System. *Value in Health*. 22(6):621-626. doi:10.1016/j.jval.2019.03.014
409. Tully S, Feng Z, Grindrod K, McFarlane T, Chan KKW, Wong WWL. Impact of Increasing Wait Times on Overall Mortality of Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma: A Discrete Event Simulation Model. *JCO Clinical Cancer Informatics*. Published online October 23, 2019. doi:10.1200/CCI.19.00086
410. Rehfuess EA, Stratil JM, Scheel IB, Portela A, Norris SL, Baltussen R. The WHO-INTEGRATE evidence to decision framework version 1.0: integrating WHO norms and values and a complexity perspective. *BMJ Global Health*. 2019;4(Suppl 1):e000844. doi:10.1136/bmjgh-2018-000844
411. Dina. EMBASE Adds New PICO Search Form | MSK Library Blog. Accessed August 18, 2020. <https://library.mskcc.org/blog/2016/02/embase-adds-new-pico-search-form/>
412. Elsevier. Using the new PICO search form. Using the new PICO search form - Elsevier. http://support-content.elsevier.com/Support%20Hub/Embase/Files%20&%20Attachements/7996-Embase_PICO%20guide_012016.pdf
413. Bannach-Brown A, Przybyła P, Thomas J, et al. Machine learning algorithms for systematic review: reducing workload in a preclinical review of animal studies and reducing human screening error. *Systematic Reviews*. 2019;8(1):23. doi:10.1186/s13643-019-0942-7
414. Marshall IJ, Wallace BC. Toward systematic review automation: a practical guide to using machine learning tools in research synthesis. *Systematic Reviews*. 2019;8(1):163. doi:10.1186/s13643-019-1074-9
415. Bernstam EV, Smith JW, Johnson TR. What is biomedical informatics? *J Biomed Inform*. 2010;43(1):104. doi:10.1016/j.jbi.2009.08.006
416. O'Sullivan AK, Thompson D, Drummond MF. Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations? *Value Health*. 2005;8(1):67-79. doi:10.1111/j.1524-4733.2005.03065.x
417. Briggs A. Economic evaluation and clinical trials: size matters. *BMJ*. 2000;321(7273):1362-1363.
418. Briggs AH, Gray AM. Power and Sample Size Calculations for Stochastic Cost-Effectiveness Analysis. *Med Decis Making*. 1998;18(2_suppl):S81-S92. doi:10.1177/0272989X98018002S10

419. Friedman LM, Furberg C, DeMets DL, Reboussin DM, Granger CB. *Fundamentals of Clinical Trials*. Vol 4. Springer; 2010.
420. Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. *Trials*. 2015;16. doi:10.1186/s13063-015-1023-4
421. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340. doi:10.1136/bmj.c332
422. Schühlen H. Pre-specified vs. post-hoc subgroup analyses: are we wiser before or after a trial has been performed? *Eur Heart J*. 2014;35(31):2055-2057. doi:10.1093/eurheartj/ehu202
423. Guyot P, Ades A, Ouwers MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. *BMC Medical Research Methodology*. 2012;12(1):9. doi:10.1186/1471-2288-12-9
424. Hunger T, Schnell-Inderst P, Sahakyan N, Siebert U. Using Expert Opinion in Health Technology Assessment: A Guideline Review. *Int J Technol Assess Health Care*. 2016;32(3):131-139. doi:10.1017/S0266462316000209
425. Leal J, Wordsworth S, Legood R, Blair E. Eliciting Expert Opinion for Economic Models: An Applied Example. *Value in Health*. 2007;10(3):195-203. doi:10.1111/j.1524-4733.2007.00169.x
426. Grigore B, Peters J, Hyde C, Stein K. A comparison of two methods for expert elicitation in health technology assessments. *BMC Medical Research Methodology*. 2016;16(1):85. doi:10.1186/s12874-016-0186-3
427. Grigore B, Peters J, Hyde C, Stein K. EXPLICIT: a feasibility study of remote expert elicitation in health technology assessment. *BMC Medical Informatics and Decision Making*. 2017;17(1):131. doi:10.1186/s12911-017-0527-0
428. Kliger D, Levy O. Mood impacts on probability weighting functions: “Large-gamble” evidence. *The Journal of Socio-Economics*. 2008;37(4):1397-1411. doi:10.1016/j.socrec.2007.08.010
429. Meyer MA, Booker JM. *Eliciting and Analyzing Expert Judgment*. Society for Industrial and Applied Mathematics; 2001. doi:10.1137/1.9780898718485
430. Guyot P, Ades AE, Beasley M, Lueza B, Pignon J-P, Welton NJ. Extrapolation of Survival Curves from Cancer Trials Using External Information. *Med Decis Making*. 2017;37(4):353-366. doi:10.1177/0272989X16670604
431. Grieve R, Hawkins N, Pennington M. Extrapolation of survival data in cost-effectiveness analyses: improving the current state of play. *Med Decis Making*. 2013;33(6):740-742. doi:10.1177/0272989X13492018
432. Jackson C, Stevens J, Ren S, et al. Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods. *Med Decis Making*. 2017;37(4):377-390. doi:10.1177/0272989X16639900
433. Kim LG, Thompson SG. Uncertainty and validation of health economic decision models. *Health Econ*. 2010;19(1):43-55. doi:10.1002/hec.1444
434. Vickers A. An Evaluation of Survival Curve Extrapolation Techniques Using Long-Term Observational Cancer Data: *Medical Decision Making*. Published online October 20, 2019. doi:10.1177/0272989X19875950
435. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. *Blood*. 2010;116(19):3724-3734. doi:10.1182/blood-2010-05-282632
436. Negrín MA, Nam J, Briggs AH. Bayesian Solutions for Handling Uncertainty in Survival Extrapolation. *Med Decis Making*. 2017;37(4):367-376. doi:10.1177/0272989X16650669
437. Annest A, Bumgarner RE, Raftery AE, Yeung KY. Iterative Bayesian Model Averaging: a method for the application of survival analysis to high-dimensional microarray data. *BMC Bioinformatics*. 2009;10(1):72. doi:10.1186/1471-2105-10-72

438. Gelber RD, Goldhirsch A, Cole BF. Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. International Breast Cancer Study Group. *Control Clin Trials*. 1993;14(6):485-499. doi:10.1016/0197-2456(93)90029-d
439. Bagust A, Beale S. Survival Analysis and Extrapolation Modeling of Time-to-Event Clinical Trial Data for Economic Evaluation: An Alternative Approach. *Medical Decision Making*. Published online July 30, 2013. doi:10.1177/0272989X13497998
440. Lambert PC. Modeling of the Cure Fraction in Survival Studies. *The Stata Journal*. 2007;7(3):351-375. doi:10.1177/1536867X0700700304
441. Mullins CD, Ogilvie S. Emerging standardization in pharmacoeconomics. *Clinical Therapeutics*. 1998;20(6):1194-1202. doi:10.1016/S0149-2918(98)80115-X
442. Ziouani S, Granados D, Borget I. How To Select The Best Comparator? An International Economic Evaluation Guidelines Comparison. *Value in Health*. 2016;19(7):A471-A472. doi:10.1016/j.jval.2016.09.726
443. European Network for Health Technology Assessment. *Methods for Health Economic Evaluations. A Guideline Based on Current Practices in Europe*. European Network for Health Technology Assessment (EUnetHTA); 2015. Accessed August 19, 2020. https://eunetha.eu/wp-content/uploads/2018/03/Methods_for_health_economic_evaluations.pdf
444. European Medicines Agency. PRIME: priority medicines. European Medicines Agency. Published September 17, 2018. Accessed June 5, 2020. <https://www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines>
445. European Medicines Agency. *Recommendations on Eligibility to PRIME Scheme*; :3. https://www.ema.europa.eu/en/documents/report/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-23-26-march-2020_en.pdf
446. Elgaz S, Kuçi Z, Kuçi S, Bönig H, Bader P. Clinical Use of Mesenchymal Stromal Cells in the Treatment of Acute Graft-versus-Host Disease. *TMH*. 2019;46(1):27-34. doi:10.1159/000496809
447. Bozkurt C, Karaöz E, Adaklı Aksoy B, Aydoğdu S, Fişgin T. The Use of Allogeneic Mesenchymal Stem Cells in Childhood Steroid-Resistant Acute Graft-Versus-Host Disease: A Retrospective Study of a Single-Center Experience. *Türk J Haematol*. 2019;36(3):186-192. doi:10.4274/tjh.galenos.2019.2019.0090
448. Jacobsohn DA, Vogelsang GB. Acute graft versus host disease. *Orphanet Journal of Rare Diseases*. 2007;2(1):35. doi:10.1186/1750-1172-2-35
449. European Medicines Agency. First two CAR-T cell medicines recommended for approval in the European Union. European Medicines Agency. Published September 17, 2018. Accessed August 21, 2020. <https://www.ema.europa.eu/en/news/first-two-car-t-cell-medicines-recommended-approval-european-union>
450. Kattamis A, Avgitidou A, Chatzopoulos S, Markouri A, Florini S, Stafylas P. PCN85 COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PAEDIATRIC AND YOUNG ADULT RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA, FROM A GREEK SOCIAL SECURITY SYSTEM PERSPECTIVE. *Value in Health*. 2019;22:S452. doi:10.1016/j.jval.2019.09.282
451. John K. Lin, Lori S. Muffy, Michael A. Spinner, James I. Barnes, Douglas K. Owens, Jeremy D. Goldhaber-Fiebert. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. *Journal of Clinical Oncology*. 2019;37(24):2105-2119. doi:10.1200/jco.18.02079
452. Tanabe P, Myers R, Zosel A, et al. Emergency Department Management of Acute Pain Episodes in Sickle Cell Disease. *Academic Emergency Medicine*. 2007;14(5):419-425. doi:10.1111/j.1553-2712.2007.tb01801.x
453. Hicks J. *The Potential of Claims Data to Support the Measurement of Health Care Quality*. RAND Corporation; 2003. https://www.rand.org/pubs/rgs_dissertations/RGSD171.html

454. Tyree PT, Lind BK, Lafferty WE. Challenges of Using Medical Insurance Claims Data for Utilization Analysis. *Am J Med Qual.* 2006;21(4):269-275. doi:10.1177/1062860606288774
455. Douven R, Burger M, Schut F. Does managed competition constrain hospitals' contract prices? Evidence from the Netherlands. *Health Economics, Policy and Law.* Published online undefined/ed:1-14. doi:10.1017/S1744133119000215
456. Kreis K, Neubauer S, Klora M, Lange A, Zeidler J. Status and perspectives of claims data analyses in Germany—A systematic review. *Health Policy.* 2016;120(2):213-226. doi:10.1016/j.healthpol.2016.01.007
457. Ferver K, Burton B, Jesilow P. The Use of Claims Data in Healthcare Research. *TOPHJ.* 2009;2(1):11-24. doi:10.2174/1874944500902010011
458. Joyce AT, Smith P, Khandker R, Melin JM, Singh A. Hidden Cost of Rheumatoid Arthritis (RA): Estimating Cost of Comorbid Cardiovascular Disease and Depression Among Patients with RA. *The Journal of Rheumatology.* 2009;36(4):743-752. doi:10.3899/jrheum.080670
459. Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. *Journal of Clinical Oncology.* 2004;22(17):3524-3530.
460. Riley GF. Administrative and Claims Records as Sources of Health Care Cost Data. *Medical Care.* 2009;47(7):S51-S55.
461. Stein JD, Lum F, Lee PP, Rich WL, Coleman AL. Use of Health Care Claims Data to Study Patients with Ophthalmologic Conditions. *Ophthalmology.* 2014;121(5):1134-1141. doi:10.1016/j.ophtha.2013.11.038
462. Perry-Duxbury M, Asaria M, Lomas J, Baal P van. Cured Today, Ill Tomorrow: A Method for Including Future Unrelated Medical Costs in Economic Evaluation in England and Wales. *Value in Health.* 2020;23(8):1027-1033. doi:10.1016/j.jval.2020.05.006
463. Karnon J. Health State Utility Values for Cost-Effectiveness Models. *PharmacoEconomics.* 2017;35(1):1-3. doi:10.1007/s40273-017-0537-x
464. Wolowacz SE, Briggs A, Belozeroff V, et al. Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report. *Value in Health.* 2016;19(6):704-719. doi:10.1016/J.JVAL.2016.06.001
465. Ohno S, Shoji A, Hatake K, Oya N, Igarashi A. Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients. *Journal of Medical Economics.* 2020;0(0):1-12. doi:10.1080/13696998.2020.1791890
466. Thielen FW, Büyükkaramikli NC, Riemsma R, et al. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma. *PharmacoEconomics.* 2019;37(8):975-984. doi:10.1007/s40273-018-0740-4
467. Guzauskas GF, Masaquel A, Reyes C, Bernaards C, Krivasi T, Veenstra DL. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US. *Journal of Medical Economics.* 2018;21(10):960-967. doi:10.1080/13696998.2018.1489254
468. Guzauskas GF, Masaquel A, Thuresson P-O, Dawson K, Veenstra DL. Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States. *Leukemia & Lymphoma.* 2019;60(7):1668-1676. doi:10.1080/10428194.2018.1551532
469. Rafia R, Pandor A, Davis S, et al. Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. *PharmacoEconomics.* 2018;36(10):1143-1151. doi:10.1007/s40273-018-0645-2

470. Muszbek N, Kadambi A, Lanitis T, et al. The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's Lymphoma. *Clinical Therapeutics*. 2016;38(3):503-515. doi:10.1016/j.clinthera.2016.01.004
471. Chen Q, Ayer T, Nastoupil LJ, Rose AC, Flowers CR. Comparing the Cost-Effectiveness of Rituximab Maintenance and Radioimmunotherapy Consolidation versus Observation Following First-Line Therapy in Patients with Follicular Lymphoma. *Value in Health*. 2015;18(2):189-197. doi:10.1016/j.jval.2014.12.017
472. Blommestein HM, Issa DE, Pompen M, et al. Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study. *European Journal of Haematology*. 2014;92(5):398-406. doi:10.1111/ejh.12264
473. Sonneveld P, Verelst SG, Lewis P, et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. *Leukemia*. 2013;27(10):1959-1969. doi:10.1038/leu.2013.185
474. Marschner N, Zacharias S, Lordick F, et al. Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer. *JAMA Netw Open*. 2020;3(3):e200643-e200643. doi:10.1001/jamanetworkopen.2020.0643
475. Wohlfarth P, Worel N, Hopfinger G. Chimeric antigen receptor T-cell therapy—a hematological success story. *Memo*. 2018;11(2):116-121. doi:10.1007/s12254-018-0409-x
476. Lim WA, June CH. The Principles of Engineering Immune Cells to Treat Cancer. *Cell*. 2017;168(4):724-740. doi:10.1016/j.cell.2017.01.016
477. Leukemia & Lymphoma Society. Chimeric Antigen Receptor (CAR) T-Cell Therapy. Accessed August 21, 2020. <https://www.lls.org/treatment/types-of-treatment/immunotherapy/chimeric-antigen-receptor-car-t-cell-therapy>
478. Tyagarajan S, Spencer T, Smith J. Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials. *Molecular Therapy - Methods & Clinical Development*. 2020;16:136-144. doi:10.1016/j.omtm.2019.11.018
479. With Kymriah nod in EU, Novartis is building a plant with up to 450 jobs. FiercePharma. Accessed August 21, 2020. <https://www.fiercepharma.com/pharma/kymriah-nod-eu-novartis-building-a-plant-up-to-450-workers>
480. European Medicines Agency. *Revlimid: EPAR - Medicine Overview*.; 2020. Accessed July 30, 2020. https://www.ema.europa.eu/en/documents/overview/revlimid-epar-medicine-overview_en.pdf
481. Marselis D, Hordijk L. From blockbuster to “nichebuster”: how a flawed legislation helped create a new profit model for the drug industry. *BMJ*. 2020;370. doi:10.1136/bmj.m2983
482. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis. *Value in Health*. 2007;10(5):336-347. doi:10.1111/j.1524-4733.2007.00187.x
483. Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. *Value in Health*. 2014;17(1):5-14. doi:10.1016/j.jval.2013.08.2291
484. van de Vooren K, Duranti S, Curto A, Garattini L. A Critical Systematic Review of Budget Impact Analyses on Drugs in the EU Countries. *Appl Health Econ Health Policy*. 2014;12(1):33-40. doi:10.1007/s40258-013-0064-7
485. Broder MS, Zambrano JM, Lee J, Marken RS. Systematic bias in predictions of new drugs' budget impact: analysis of a sample of recent US drug launches. *Curr Med Res Opin*. 2018;34(5):765-773. doi:10.1080/03007995.2017.1320276
486. Zwaap J, Knies S, van der Meijden C, Staal P, van der Heiden L. *Cost-Effectiveness in Practice*.; 2015. <https://english.zorginstituutnederland.nl/binaries/zinl-eng/documents/reports/2015/06/16/cost-effectiveness-in-practice/Cost-effectiveness+in+practice.pdf>

487. Charrot S, Hallam S. CAR-T Cells: Future Perspectives. *HemaSphere*. 2019;3(2):e188. doi:10.1097/hs9.000000000000188
488. Bach PB, Giral SA, Saltz LB. FDA Approval of Tisagenlecleucel: Promise and Complexities of a \$475 000 Cancer Drug. *JAMA*. 2017;318(19):1861-1862. doi:10.1001/jama.2017.15218
489. Zavras P, Wang Y, Gandhi A, Lontos K, Delgoffe G. Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date. *Onco Targets Ther*. 2019;12:4543-4554. doi:10.2147/OTT.S177844
490. Uyl-de Groot CA, Heine R, Krol M, Verweij J. Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe. *Cancers*. 2020;12(8):2313. doi:10.3390/cancers12082313